A record Sun Pharma acquisition signals global ambitions. However, significant infrastructure, capital, and policy gaps could hinder India’s aspirations to become a leading R&D powerhouse. The recent acquisition underscores the growing intent of Indian pharmaceutical companies to expand their footprint internationally, particularly as they seek to compete with established players in China.
China has rapidly advanced its pharmaceutical sector, benefiting from substantial government support and investment in research and development. In contrast, India’s industry faces challenges such as regulatory hurdles and inconsistent funding, which may impede its growth trajectory. As Indian firms strive to innovate and enhance their global competitiveness, addressing these systemic issues will be crucial. The future of India’s pharma sector hinges on its ability to overcome these barriers and effectively leverage its existing strengths in generics and biosimilars.
Open the full market picture for your next decision →
